Nanomedicine-based cancer immunotherapies developed by reprogramming tumor-associated macrophages
- 21 January 2021
- journal article
- review article
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 13 (9), 4705-4727
- https://doi.org/10.1039/d0nr08050k
Abstract
The tumor microenvironment (TME) is a complex composed of tumor extracellular matrix, fibroblasts, blood vessels, and immune cells, promoting the occurrence and development of tumors by secreting a variety of growth factors, hydrolase, and inflammatory factors. Tumor-associated macrophages (TAMs) constitute the largest number of immune cells in the TME, and they have a “double-edged sword” effect on tumor growth, invasion, metastasis, angiogenesis, and immunosuppression. Under the regulation of different cytokines in the TME, the bidirectional TAMs can switch their phenotypes between tumoricidal M1-like and pro-tumorigenic M2-like macrophages. TAMs polarization suggests that scientists can use this property to design drugs targeting this regulation as a promising immunotherapy strategy to enhance tumor therapy efficiency. In this review, we summarize a brief introduction of TAMs and their implications for tumorigenesis. Next, we review recent advances in designing various functionalized nanomedicines and their applications in nanomedicine-based cancer therapies that target TAMs by killing them, inhibiting macrophage recruitment, and repolarizing them from pro-tumorigenic M2-like to tumoricidal M1-like macrophages. Simultaneously, the regulation of nanomedicines on the signaling pathways accounting for these effects is also summarized. This review will not only provide background scientific information for the understanding of TAMs and their roles in cancer treatment. It will also help scientists design nanomedicines based on tumor TAMs, which can help achieve better clinical treatment outcomes for tumors.Funding Information
- National Natural Science Foundation of China (21877049, 21701051)
- K. C. Wong Education Foundation
- Natural Science Foundation of Guangdong Province (2017A030313051)
- China Postdoctoral Science Foundation (2018T110922)
This publication has 166 references indexed in Scilit:
- ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophagesCell Research, 2013
- The CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implicationsCurrent Opinion in Immunology, 2012
- FcRγ Activation Regulates Inflammation-Associated Squamous CarcinogenesisCancer Cell, 2010
- Stromal cell‐derived CSF‐1 blockade prolongs xenograft survival of CSF‐1‐negative neuroblastomaInternational Journal of Cancer, 2009
- CD4+ T Cells Regulate Pulmonary Metastasis of Mammary Carcinomas by Enhancing Protumor Properties of MacrophagesCancer Cell, 2009
- Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppressionMolecular Immunology, 2008
- Alternative M2 Activation of Kupffer Cells by PPARδ Ameliorates Obesity-Induced Insulin ResistanceCell Metabolism, 2008
- Adipocyte-Derived Th2 Cytokines and Myeloid PPARδ Regulate Macrophage Polarization and Insulin SensitivityCell Metabolism, 2008
- Macrophage-specific PPARγ controls alternative activation and improves insulin resistanceNature, 2007
- The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapiesThe Journal of Pathology, 2002